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Fentazin (perphenazine), a phenothiazine, increases circulating prolactin levels by inhibiting prolactin inhibiting factor. (Pearson et al., Trans. Am. Physicns, 1969, 32, 225 Adenocarcinomata from the Fentazin treated animals displayed greater metabolism of testosterone than those from control animals whereas the transformation of dehydroepiandrosterone was similar in both groups. The increase in testosterone metabolism was largely accounted for by a significant increase in 5-co-reductase activity. These results suggest that prolactin may modify the intracellular environment of steroid hormones in rat adenocarcinomata. Thirty-two patients with acute nonlymphocytic leukaemia (22 myeloid, 2 monoblastic, 3 myelomonoblastic, 2 promyelocytic, 3 blast crisis) have been treated with combined daunorubincin 1 mg/kg i.v. x 1 cytosine arabinoside 2 mg/kg x 5 and vincristine 1 mg i.v. x 1 in 5-day cycles and followed by 6-mercaptopurine and cyclophosphamide when remission was induced, with reinduction at 3-monthly intervals. Sixty per cent of patients went into full remission, which has lasted from 6 months to 2 years. Two patients with acute promyelocytic leukaemia developed coagulation problems which were controlled by EACA and then went into full remission. Two patients with acute monoblastic and myelomonoblastic leukaemia went into full remission on this programme.
One patient who was extremely ill during induction of remission developed a severe neuropathy. Alopecia was a problem with higher dosage of daunorubicin and cardiotoxicity occurred in 2 patients. Reinduction at 3-monthly intervals with triple chemotherapy was smooth and in our opinion contributes to the prolonged remission in these cases. Age group did not significantly affect remission rate. The combination of estimations of carcinoembryonic antigen (CEA) with certain serum enzymes (y glutamyl transpeptidase (yGT) and leucine aminopeptidase (LAP) can enhance the separation of controls from patients with primary colorectal cancer and those with metastatic involvement of the liver.
yGT contributes to this discrimination in both the primary and secondary case. The mean values were: (i) control 13-94 ± 7-65; (ii) primary 21'65 i 12-20 and (iii) metastatic 139-34 ± 96-22.
On the other hand, the LAP was elevated only in metastatic involvement of the liver and did not rise before the yGT exceeded 100 units: (i) control 41-55 ± 9-20; (ii) primary 40-27 + 14-38 and (iii) metastatic 96-81 + 50-39.
